1. Home
  2. DRH vs PHVS Comparison

DRH vs PHVS Comparison

Compare DRH & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Diamondrock Hospitality Company

DRH

Diamondrock Hospitality Company

HOLD

Current Price

$8.64

Market Cap

1.8B

Sector

Real Estate

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$27.75

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRH
PHVS
Founded
2004
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.6B
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
DRH
PHVS
Price
$8.64
$27.75
Analyst Decision
Hold
Buy
Analyst Count
7
9
Target Price
$9.32
$39.44
AVG Volume (30 Days)
4.3M
513.8K
Earning Date
11-06-2025
11-12-2025
Dividend Yield
3.71%
N/A
EPS Growth
N/A
N/A
EPS
0.26
N/A
Revenue
$1,125,008,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$15.17
N/A
P/E Ratio
$33.50
N/A
Revenue Growth
0.95
N/A
52 Week Low
$6.19
$11.51
52 Week High
$9.89
$29.80

Technical Indicators

Market Signals
Indicator
DRH
PHVS
Relative Strength Index (RSI) 48.68 58.66
Support Level $8.57 $23.80
Resistance Level $9.13 $28.63
Average True Range (ATR) 0.23 2.21
MACD -0.05 0.30
Stochastic Oscillator 9.16 70.58

Price Performance

Historical Comparison
DRH
PHVS

About DRH Diamondrock Hospitality Company

Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The revenue is divided between room, food and beverage, and others. The room segment contributes the majority of the revenue. The firm's customers include leisure transients, business transients, and group customers.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: